The global In-Vitro Fertilization market size was valued at USD 16.68 billion in 2018 and is estimated to expand at a CAGR of 10.2% over the forecast period. Increase in the cases of infertility and development of advanced technologies such as lensless imaging of sperms are likely to drive the growth.
According to the American Society for Reproductive Medicine (ASRM), infertility affects around 6.7 million women in the U.S, which accounts for around 11.0% of the reproductive population. Moreover, 25% of the couples have more than one factors leading to infertility.
The average age of women and men getting married and having their first child is increasing. This trend has increased the number of women seeking the IVF treatment. Moreover, to focus on their career, many women freeze their eggs to have the child at a later stage.
Government funding to encourage egg/sperm freezing to bring down the chances of multiple pregnancies, technological advancements that enable pre-identification of genetic disorders, and various industrial revolutions are expected to boost the market growth.
Asia Pacific accounted for the largest share of the IVF market in terms of the number of IVF cycles performed in 2018 due to the large target population, low cost of treatment as compared to developed regions, and availability of advanced technology. Japan, China, and India were the major regional contributors.
In December 2016, the Ontario government announced a USD 50 million fertility program to cover IVF treatment for 5,000 people. Furthermore, the Singapore government offers around 75% co-funding for various Assisted Reproductive Technology (ART) procedures such as In-Vitro Fertilization (IVF), Gamete Intrafallopian Transfer (GIFT), and Intracytoplasmic Sperm Injection (ICSI). In January 2015, the Centers for Disease Control and Prevention (CDC) reported that the use of ICSI has increased from 36.4% in 1996 to around 76.2% in 2012.
To increase the success rate of IVF, researchers have introduced techniques used prior to the IVF procedure. Presently, advanced techniques, such as assisted hatching, vitrification, egg/sperm freezing, Percutaneous Epidydimal Sperm Aspiration and Testicular Sperm Extraction (PESA and TESE), mini IVF, three-parent IVF, and genetic diagnosis, are used.
With the use of PGD technique, scientists can easily identify the diseased DNA and can change it with the healthy donor DNA, thereby ensuring a healthy childbirth. With the expected rise in demand, industry players are bringing in new molecular diagnostic technologies, which could further drive the In-Vitro Fertilization (IVF) market.
In April 2016, CombiMatrix Corporation launched Combi PGD, a diagnostic technique used prior to embryo implantation. Introduction of technologically advanced systems by the market players such as Embryoscope Time-Lapse System (Vitrolife AB) is one of the high impact rendering drivers.
The IVF instrument consists of culture media, capital equipment, and IVF disposable devices. In 2018, culture media held the largest market share, attributed to high government funding, increase in research activities to improve the culture media, and ability to preserve sperm without reducing their quality.
Cryopreservation media, semen processing media, ovum processing media, and embryo culture media are the major media used during in-vitro fertilization. With the establishment of huge egg cryobanks, the demand for egg processing media is also expected to rise in the forthcoming years.
With the need for high standards of sterile conditions and strict regulatory mandates, industry players are introducing disposable devices such as needles, slides, chambers, and others. Hence, disposable devices segment is likely to grow at the fastest rate during the forecast period.
With the increasing number of patient opting for in-vitro fertilization and gamete freezing, the demand or capital equipment is anticipated to witness growth. As a result, companies are developing equipment with high automation standards.
On the basis of type, the market has been segmented into fresh nondonor, frozen nondonor, fresh donor, and frozen donor. Fresh non donor segment accounted for the largest market share in 2018 due to the high success rate in the first attempt.
Frozen nondonor segment is likely to witness the fastest growth in the forthcoming years as the procedure can be performed in complicated cases such as on a patient suffering from Ovarian Hyperstimulation Syndrome (OHSS). Additionally, better implantation rate, higher live birth rate, more birth weight, lower miscarriage rate, and reduced cases of ectopic pregnancy are expected to drive demand for the procedure during the forecast period.
Fertility clinics segment held the largest market share in 2018 and is likely to lead throughout the forecast period. With rise in demand for ART treatments, the number of fertility clinics and ART centers is increasing considerably.
Licensed fertility clinics offer counselling to the couples having problems in conceiving. Based on the severity of their problems, doctors and specialists plan out IVF treatments for couples. Fertility clinics are providing state-of-the-art equipment such as micromanipulation, non-invasive Radio Frequency Identification (RFID) tags, and others. This factor is further expected to propel the market growth over the forecast period.
In 2018, Europe led the market, as it is the first region to come up with this procedure, to remove the title experimental from cryopreservation of eggs, and the first one to legally approve the three parent IVF or the mitochondrial transfer technique. Furthermore, medical tourism in Europe is driving the growth. People are flying to Czech Republic from the U.S. due to affordability of the procedure.
Institutes are introducing newer techniques, offering better success rate at an affordable cost. For instance, the Valencian Infertility Institute in Spain has developed various fertility methods to increase the success rate of the treatment. Germany, France, and U.K. are the major contributing countries in the region. In France about 19,000 ART births take place every year. Furthermore, in July 2015, France legislation allowed legal recognition to surrogate children to enable them to have French nationality and rights as other French children.
North America is also expected to witness increasing demand for fertility treatment in the forthcoming years. In April 2016, Reprogenetics published its research, which validated the use of High-Resolution Next Generation Sequencing (HR-NGS) techniques. The company is the largest genetic laboratory in U.S. that is providing Pre-Implantation Genetic Diagnosis for Aneuploidy (PGD-A). The new test detects mosaic embryos, which can help select healthy embryo during the procedure.
The Toronto Centre for Advanced Reproductive Technology (TCART) was the first Canadian Clinic to provide free IVF to 60 women to experiment the AUGMENT rejuvenating technique. The technique allowed older cells to rejuvenate by taking smaller cells from the outer ovary lining. It allowed young cell harvesting and higher treatment success rate.
The demand for in-vitro fertilization is expected to boom in Asia Pacific due to fertility tourism, increasing foreign investment in the economically developing countries, and the changing regulatory landscape. In November 2017, Warburg Pincus, a private equity firm, was in the last stage of negotiations to procure minority stake in Indira IVF Hospital Pvt. Ltd, which is one of the leading fertility hospital chains in India.
IVF market has a huge opportunity in Japan owing to the introduction of newer techniques such as AUGMENT and defined regulatory framework. IN August 2016, OvaScience announced the finalization of its commercial agreement with IVF Japan Group, through which AUGMENT treatment would be made available to women. In Japan, the couples can apply for co-funding for a maximum of three cycles with USD 1,920 for each cycle. The couple, whose income is over USD 94,000 per year cannot qualify for the funding option.
In January 2013, Oocyte Donation Network (OD-NET), the first Japanese NPO bank was started and in May 2013, thirty-eight women were eligible, out of the 100 who applied. This organization only funds for the actual expenses and not for the eggs. Surrogacy has been banned by the Japan Society of Obstetrics and Gynecology and Health, Labor, and Welfare Ministry.
The Asia Pacific Initiative on Reproduction (ASPIRE), a task force of clinicians and scientists involved in the monitoring and management of fertility and ART. It promotes awareness regarding ART and infertility and enhances the regional infertility-related services.
Researchers from the University of Adelaide in Australia and the University of Medicine and Pharmacy in Vietnam in the study (The New England Journal of Medicine) stated that the pregnancy and live birth rates were equal in the group of women implanted with fresh embryos compared to frozen embryos.
In January 2018, it was announced that Singapore Medical Group (SMG) took the stake in the City Fertility Centre or CFC Global, which is one of the leading IVF specialists in Australia. The partnership is expected to increase referrals in Vietnam and other nations due to increasing demand for fertility and women’s health.
Technological advancements are expected to drive the market in Australia over the forecast period. In March 2018, it was reported that smart TV app is used by the Monash IVF to consult fertility patients in China, after the clinic entered into an agreement with AC International Medical Tourism (Melbourne), which targets the Chinese market. Monash IVF, fertility clinic in Melbourne, entered into a partnership with platform BabySmart, which enables the Chinese patients to have face to face consultation with the clinicians in Australia.
Key industry contributors are OvaScience; EMD Serono Inc.; Vitrolife AB; Irvine Scientific; Cook Medical Inc.; Cooper Surgical Inc.; Genea Biomedx; Thermo Fisher Scientific Inc.; Progyny, Inc.; and Boston IVF. Development of innovative product and their commercialization, mergers, and geographical expansions are the key strategies adopted by the market players.
In August 2015, OvaScience announced the results of its first published analysis comparing AUGMENT fertility treatment with a standard IVF. The results showed a significantly higher rate of selection and transfer of embryos as compared to the standard treatment.
In May 2015, EMD collaborated with Genea Biomedx to strengthen its position in the fertility market by providing fertility technologies. In January 2018, NMC Health, a UAE based healthcare provider, acquired 100% share of the Fakih IVF, a major player in the IVF services market.
Base year for estimation
Actual estimates/Historical data
2015 - 2017
2019 - 2026
Revenue in USD Million & CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America, & MEA
U.S., Canada, U.K., Germany, France, Italy, Spain, Netherlands, Switzerland, Belgium, Japan, China, India, Brazil, Mexico, & South Africa
Revenue forecast, company share, competitive landscape, growth factors & trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global In-Vitro Fertilization (IVF) market report based on instrument, type, end use, and region:
Instrument Outlook (Revenue, USD Million, 2015 - 2026)
Type Outlook (Revenue, USD Million, 2015 - 2026)
End Use Outlook (Revenue, USD Million, 2015 - 2026)
Hospitals & others
Regional Outlook (Revenue, USD Million, 2015 - 2026)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
We value your investment and offer free customization with every report to fulfil your exact research needs.
Toll Free: 1-888-202-9519
Email: [email protected]
Phone: +91-20-67491414 (Sales)
Email: [email protected]
Email: [email protected]
Email: [email protected]
Email: [email protected]